Theravance Biopharma Net Current Debt 2012-2025 | TBPH

Theravance Biopharma net current debt from 2012 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.

Theravance Biopharma Net Current Debt 2012-2025 | TBPH

Theravance Biopharma net current debt from 2012 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.5B
Zoetis (ZTS)$68B
Daiichi Sankyo, - (DSNKY)$46.9B
Takeda Pharmaceutical (TAK)$46.6B
BeOne Medicines - (ONC)$32.5B
Sandoz Group AG (SDZNY)$26.5B
Summit Therapeutics (SMMT)$20.5B
Merck (MKKGY)$17.3B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$11.1B
Stevanato Group S.p.A (STVN)$8.5B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B